These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16508734)

  • 41. [Capecitabine].
    Yamaguchi K; Shimamura T; Tada M
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Phase I study of postoperative concurrent chemoradiation with capecitabine as adjuvant treatment for stage II/III operable rectal cancer].
    Jin J; Li YX; Liu YP; Wang WH; Li T; Li N; Song YW
    Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):393-6. PubMed ID: 17045010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute coronary syndrome induced by capecitabine therapy.
    Wijesinghe N; Thompson PI; McAlister H
    Heart Lung Circ; 2006 Oct; 15(5):337-9. PubMed ID: 16697705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Capecitabine cardiac toxicity presenting as effort angina: a case report.
    Lestuzzi C; Crivellari D; Rigo F; Viel E; Meneguzzo N
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):700-3. PubMed ID: 20093950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
    Villalón G; Martín JM; Pinazo MI; Calduch L; Alonso V; Jordá E
    Am J Clin Dermatol; 2009; 10(4):261-3. PubMed ID: 19489659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Oral cytostatic drug in colorectal carcinoma. Selective tumor therapy at home].
    MMW Fortschr Med; 2001 Mar; 143(13):51-2. PubMed ID: 11332023
    [No Abstract]   [Full Text] [Related]  

  • 47. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
    Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ;
    Oncology; 2004; 67(2):117-22. PubMed ID: 15539915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of capecitabine dosing in colorectal cancer.
    Sun W
    Clin Colorectal Cancer; 2010 Jan; 9(1):31-9. PubMed ID: 20100686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toxic encephalopathy induced by capecitabine.
    Niemann B; Rochlitz C; Herrmann R; Pless M
    Oncology; 2004; 66(4):331-5. PubMed ID: 15218302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Hand-foot syndrome with capecitabine therapy].
    Marini A; Hengge UR
    Hautarzt; 2007 Jun; 58(6):532-6. PubMed ID: 16897045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial).
    Veerasarn V; Phromratanapongse P; Lorvidhaya V; Lertsanguansinchai P; Lertbutsayanukul C; Panichevaluk A; Boonnuch W; Chinswangwatanakul V; Lohsiriwat D; Rojanasakul A; Thavichaigarn P; Jivapaisarnpong P
    J Med Assoc Thai; 2006 Nov; 89(11):1874-84. PubMed ID: 17205868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
    Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
    Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.
    Sykes AJ; Slevin NJ; MacDougall RH; Ironside JA; Mais KL
    Radiother Oncol; 2004 Apr; 71(1):81-4. PubMed ID: 15066299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
    Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
    J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metastatic hidradenocarcinoma: efficacy of capecitabine.
    Jouary T; Kaiafa A; Lipinski P; Vergier B; Lepreux S; Delaunay M; Taïeb A
    Arch Dermatol; 2006 Oct; 142(10):1366-7. PubMed ID: 17043204
    [No Abstract]   [Full Text] [Related]  

  • 56. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
    Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
    Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
    Jin J; Li YX; Liu YP; Wang WH; Song YW; Li T; Li N; Yu ZH; Liu XF
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):725-9. PubMed ID: 16242260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
    Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
    Tipples K; Kolluri RB; Raouf S
    J Oncol Pharm Pract; 2009 Dec; 15(4):237-9. PubMed ID: 19276137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
    Chua D; Wei WI; Sham JS; Au GK
    Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.